Abstract
Background: To determine if marijuana legalization was associated with reduced opioid mortality.
Study design: The United States (US) opioid mortality trend during the 2010-2019 decade was compared in states and District of Columbia (jurisdictions) that had implemented marijuana legalization with states that had not. Acceleration of opioid mortality during 2020, the first year of the coronavirus disease 2019 (COVID-19) pandemic, was also compared in recreational and medicinal-only legalizing jurisdictions.
Methods: Joinpoint methodology was applied to the Centers for Disease Control and Prevention WONDER data. Trends in legalizing jurisdictions were cumulative aggregates.
Results: The overall opioid and fentanyl death rates and the percentage of opioid deaths due to fentanyl increased more during 2010-2019 in jurisdictions that legalized marijuana than in those that did not (pairwise comparison p = 0.007, 0.05, and 0.006, respectively). By 2019, the all-opioid and fentanyl death rates were 44 and 50 percent greater in the legalizing than in the nonlegalizing jurisdictions, respectively. When the COVID-19 pandemic hit in 2020, jurisdictions that implemented recreational marijuana legalization before 2019 had significantly greater increases in both overall opioid and fentanyl death rates than jurisdictions with medicinal-only legalization. For all-opioids, the mean (95 percent confidence interval) 2019-to-2020 increases were 46.5 percent (36.6, 56.3 percent) and 29.1 percent (20.2, 37.9 percent), respectively (p = 0.02). For fentanyl, they were 115.6 percent (80.2, 151.6 percent) and 55.4 percent (31.6, 79.2 percent), respectively (p = 0.01).
Conclusions: During the past decade, marijuana legalization in the US was associated at the jurisdiction level with a greater acceleration in opioid death rate. An even greater increase in opioid mortality occurred in recreational-legalizing jurisdictions with the onset of the COVID-19 pandemic. Marijuana legalization is correlated with worsening of the US opioid epidemic.
Publisher
Weston Medical Publishing
Reference74 articles.
1. Victor B, Hager K, Stacy S: Re-legalizing cannabis for medical use in the USA. J Public Health (Oxf). 2022; 44(3): 679-684. DOI: 10.1093/pubmed/fdab066.
2. State Medical Cannabis Laws, National Conference of State Legislatures (NCSL): Available at https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx#3. Accessed May 15, 2023.
3. Arnold JF, Sade RM: Regulating marijuana use in the United States: Moving past the gateway hypothesis of drug use. J Law Med Ethics. 2020; 48(2): 275-278. DOI: 10.1177/1073110520935339.
4. The United States Department of Justice: Presidential proclamation on marijuana possession. Available at https://www.justice.gov/pardon/presidential-proclamation-marijuanapossession. Accessed May 15, 2023.
5. Statista: Sales of legal recreational cannabis in the United States from 2021 to 2026. Available at https://www.statista.com/statistics/933384/legal-cannabis-sales-forecast-us/. Accessed May 15, 2023.